Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.
Evogene Ltd. reports developments as a computational chemistry company focused on generative design of small molecules for pharmaceutical and agricultural applications. Its recurring updates center on ChemPass AI™, a proprietary generative AI platform used to explore chemical space and optimize small-molecule candidates across multiple parameters.
Company news also covers financial results, strategic refocusing around ChemPass AI™, collaborations in drug discovery and ag-chemical development, and subsidiary activity. Reported subsidiary themes include Casterra's castor seed varieties and castor farming systems for bio-based industries, AgPlenus work on novel herbicides and fungicides, Biomica microbiome-based therapeutics, and Nasdaq listing-compliance matters for EVGN ordinary shares.
Evogene Ltd. (NASDAQ: EVGN) reported its financial results for H1 2021, revealing a cash position of $65.4 million. The company is advancing on its strategy to enhance shareholder value via its subsidiaries, considering spin-offs for independent trading. Biomica showcased significant anti-tumor activity for its candidate BMC128, with plans for a proof-of-concept trial. However, cash usage increased to $11.3 million in H1 2021, driven by product development investments, and net loss rose to $6.9 million in Q2 2021, compared to $4.8 million in Q2 2020.
Evogene Ltd. (NASDAQ: EVGN) announced that President and CEO Ofer Haviv will present at the Jefferies Virtual Industrials Conference on August 3, 2021, at 09:00 AM EST. The presentation will highlight Evogene's disruptive technologies and tailored engines for product discovery across its subsidiaries. Investors interested in meeting Mr. Haviv can contact Evogene's Investor Relations team. Evogene is focused on revolutionizing life-science product development using its Computational Predictive Biology platform, targeting sectors like human health and agriculture.
Evogene Ltd. (NASDAQ: EVGN) announces its second quarter financial results will be released on August 11, 2021. Incoming Chairperson of the Board, Ms. Sarit Firon, will discuss her vision during the conference call at 09:00 AM Eastern Time. The call can be accessed via phone or live webcast on the company's website. The replay will be available shortly after the call until August 13, 2021. Evogene focuses on life-science product development through its Computational Predictive Biology (CPB) platform, targeting sectors like human health and agriculture.
AgPlenus Ltd., a subsidiary of Evogene (NASDAQ: EVGN), announced successful results from a Proof of Concept (POC) testing of its herbicide candidate APH1, demonstrating resistance traits in modified tobacco plants. The greenhouse tests showed that these plants remained unharmed when treated with APH1, indicating potential for developing resistant commercial crops, including soybeans. This advancement is crucial as global herbicide resistance continues to rise, with the market expected to reach $34 billion in 2022. The company aims to leverage this success to broaden its offerings in crop protection.
Evogene Ltd. (NASDAQ: EVGN) has announced the appointment of Ms. Sarit Firon as the new Chairperson of the Board, pending her re-election at the upcoming Annual General Meeting. This follows the decision of Mr. Martin Gerstel, the current Chairperson, to step down after nearly 20 years. Firon, a seasoned investor with over 27 years of experience, has been on Evogene's board since 2016 and is expected to guide the company through its promising product pipelines in various life sciences markets. Both Gerstel and CEO Ofer Haviv expressed confidence in Firon's leadership capabilities.
Evogene Ltd. (NASDAQ: EVGN) announced its Q1 2021 financial results, reporting a loss of $7.1 million and an operating loss of $6.3 million, slightly improved from Q1 2020. The company retains a strong cash position with $70.1 million in reserves. Significant milestones in its subsidiaries' pipelines are anticipated in 2021-2022, including product launches and strategic collaborations, particularly with Corteva. R&D expenses decreased to $4.3 million, while G&A expenses rose to $1.5 million. Evogene aims to enhance value recognition in capital markets.
Lavie Bio Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), has appointed Russ Putland as Vice President Commercial. With over 30 years of experience in multinational agriculture, including leading a $175 million sales organization at DuPont, Putland will oversee Lavie Bio's commercial strategy. His focus will be on building partnerships and driving revenue from ag-biological products. Lavie Bio aims to enhance food quality and agriculture productivity through microbiome-based solutions. The company expects Putland's leadership to accelerate the commercialization of its product pipeline.
Evogene Ltd. (NASDAQ: EVGN) will announce its financial results for Q1 2021 on May 26, 2021. CEO Ido Dor will discuss recent developments at Lavie Bio Ltd. during the conference call scheduled for 09:00 AM ET. Investors can join by dialing US toll-free number +1-888-281-1167 or internationally +972-3-918-0609. A replay will be available shortly after the call, accessible until May 28, 2021. Evogene focuses on computational biology for life-science advancements across human health and agriculture, utilizing its CPB platform to enhance product development.
Biomica, a biopharmaceutical company focused on microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced that CEO Dr. Elran Haber will present at the Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021. The presentation will highlight Biomica's innovative approaches using a Computational Predictive Biology platform to develop therapies targeting antibiotic-resistant bacteria and gastrointestinal disorders. One-on-one meetings will be available for further discussions during the summit.
Biomica Ltd., a subsidiary of Evogene (NASDAQ: EVGN), announced positive pre-clinical results for its live biotherapeutic product BMC128 in a melanoma model. The study showed that combining BMC128 with Immune Checkpoint Inhibitors (ICI) significantly improved anti-tumor activity, achieving a 13% Objective Response Rate and doubling tumor growth inhibition compared to ICI alone. These findings support BMC128's potential in treating solid tumors and follow earlier positive results in breast cancer models. Biomica is progressing towards a first-in-human clinical trial expected later this year.